Bruker/$BRKR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bruker
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Ticker
$BRKR
Sector
Primary listing
Employees
11,396
Headquarters
Website
Bruker Metrics
BasicAdvanced
$5.9B
74.46
$0.52
1.20
$0.20
0.52%
Price and volume
Market cap
$5.9B
Beta
1.2
52-week high
$64.64
52-week low
$28.53
Average daily volume
3.7M
Dividend rate
$0.20
Financial strength
Current ratio
1.605
Quick ratio
0.622
Long term debt to equity
129.762
Total debt to equity
132.746
Dividend payout ratio (TTM)
38.32%
Interest coverage (TTM)
6.20%
Profitability
EBITDA (TTM)
557.6
Gross margin (TTM)
48.99%
Net profit margin (TTM)
2.31%
Operating margin (TTM)
10.08%
Effective tax rate (TTM)
44.83%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
3.40%
Return on equity (TTM)
4.07%
Valuation
Price to earnings (TTM)
74.464
Price to revenue (TTM)
1.708
Price to book
3.23
Price to tangible book (TTM)
-3.68
Price to free cash flow (TTM)
119.29
Free cash flow yield (TTM)
0.84%
Free cash flow per share (TTM)
0.325
Dividend yield (TTM)
0.52%
Forward dividend yield
0.52%
Growth
Revenue change (TTM)
10.36%
Earnings per share change (TTM)
-78.21%
3-year revenue growth (CAGR)
11.62%
10-year revenue growth (CAGR)
7.46%
3-year earnings per share growth (CAGR)
-33.89%
10-year earnings per share growth (CAGR)
4.05%
3-year dividend per share growth (CAGR)
3.57%
What the Analysts think about Bruker
Analyst ratings (Buy, Hold, Sell) for Bruker stock.
Bulls say / Bears say
Q1 2025 revenue reached $801.4 million, up 11.0% year-over-year, driven by 2.9% total organic growth and 5.1% organic growth in the core BSI segment (Business Wire).
Bruker rolled out a cost reduction plan aimed at cutting annual expenses by $100 million to $120 million in fiscal 2026, supporting efforts to expand margins and grow EPS despite softening demand (Business Wire).
Bruker secured more than $27 million in multi-year contracts for explosives and chemical trace detection solutions in aviation security and defense, diversifying its revenues and strengthening recurring consumables and service revenue streams (Business Wire).
Organic revenue decreased 7.0% year-over-year in Q2 2025, revealing ongoing weak demand in the U.S. academic, biopharma, and industrial sectors (Business Wire).
Bruker revised its full-year 2025 non-GAAP EPS forecast downward to $1.95–$2.05 from $2.40–$2.48, versus $2.41 in fiscal 2024, indicating sustained profit challenges and ongoing demand uncertainty (Business Wire).
Bruker’s cash and cash equivalents declined to $92 million at the end of Q2 2025, while total long-term debt increased to $2.44 billion, raising the company’s leverage and potential interest expense (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
Bruker Financial Performance
Revenues and expenses
Bruker Earnings Performance
Company profitability
Bruker News
AllArticlesVideos
Bruker Announces Orders for NIH- and NSF-Funded NMR Systems from New York Structural Biology Center, University of Delaware and Northwestern University
Business Wire3 weeks ago
Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock
Business Wire2 months ago
These Analysts Slash Their Forecasts On Bruker After Weaker-Than-Expected Q2 Results
Benzinga3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bruker stock?
Bruker (BRKR) has a market cap of $5.9B as of October 23, 2025.
What is the P/E ratio for Bruker stock?
The price to earnings (P/E) ratio for Bruker (BRKR) stock is 74.46 as of October 23, 2025.
Does Bruker stock pay dividends?
Yes, the Bruker (BRKR) stock pays dividends to shareholders. As of October 23, 2025, the dividend rate is $0.2 and the yield is 0.52%. Bruker has a payout ratio of 38.32% on a trailing twelve-month basis.
When is the next Bruker dividend payment date?
The next Bruker (BRKR) dividend payment date is unconfirmed.
What is the beta indicator for Bruker?
Bruker (BRKR) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.